EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Bioequivalence of Two Firsekibart Subcutaneous Formulations: A Randomized, Double‐Blind, Single‐Dose, Parallel‐Group Study in Healthy Chinese Participants

Yehua Xie, Xiao Li, Yushi Chen, Guangli Ma, Fei Gu, Yuling Lian, Xu Zhang, Xiaolan Yong

Clinical Pharmacology in Drug Development · 2026-07 · 15 (7)

DOI: 10.1002/cpdd.70077 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 20.07.2026. Verfasst von Yehua Xie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We evaluated the pharmacokinetic (PK) bioequivalence and safety of a new formulation of firsekibart (solution for injection) compared with firsekibart lyophilized powder for solution. In this randomized, double‐blind, parallel‐group study, healthy Chinese adult males received a single subcutaneous dose of 200 mg firsekibart solution for injection (test product, T) or firsekibart powder for solution (reference product, R), followed through Day 141. The primary objective was to evaluate PK bioequivalence between T and R, concluded if least‐squares geometric mean ratio (GMR) 90% confidence intervals (CIs) were within 80.00%–125.00%. Safety was also evaluated. A total of 181 participants received T (N = 90) or R (N = 91). PK profiles were comparable between T and R: least‐squares GMRs (T/R; 90% CI) for the maximum serum concentration, area under the concentration–time curve (AUC) from time zero to the last time of quantifiable concentration, and AUC from time 0 to infinity were 104.26% (98.11%, 110.80%), 103.45% (98.15%, 109.04%), and 102.14% (96.75%, 107.83%), respectively. Most treatment‐emergent adverse events were mild/moderate and generally comparable between T and R, with no treatment‐related serious adverse events reported. Firsekibart solution for injection was bioequivalent to firsekibart lyophilized powder for solution for injection in healthy Chinese males, with no new safety signals identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAdultHumansMaleYoung AdultArea Under CurveChinaDouble-Blind MethodHealthy VolunteersInjections, SubcutaneousPowdersTherapeutic Equivalency

Stichwörter der Autor:innen

bioequivalencefirsekibartinterleukin‐1β (IL‐1β)pharmacokineticssafety

Substanzen

PowdersAntibodies, Monoclonal

Autor:innen und Institutionen

  • Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
  • Phase I Clinical Trial Center, Chengdu Xinhua Hospital, Chengdu, China.

Förderung

  • Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China

Zitieren

APA

Xie, Y., Li, X., Chen, Y., Ma, G., Gu, F., Lian, Y., Zhang, X., & Yong, X. (2026). Bioequivalence of Two Firsekibart Subcutaneous Formulations: A Randomized, Double‐Blind, Single‐Dose, Parallel‐Group Study in Healthy Chinese Participants. Clinical Pharmacology in Drug Development, 15(7). https://doi.org/10.1002/cpdd.70077

Vancouver

Xie Y, Li X, Chen Y, Ma G, Gu F, Lian Y, et al. Bioequivalence of Two Firsekibart Subcutaneous Formulations: A Randomized, Double‐Blind, Single‐Dose, Parallel‐Group Study in Healthy Chinese Participants. Clinical Pharmacology in Drug Development. 2026;15(7). doi:10.1002/cpdd.70077

BibTeX
@article{Xie2026,
  author = {Xie, Yehua and Li, Xiao and Chen, Yushi and Ma, Guangli and Gu, Fei and Lian, Yuling and Zhang, Xu and Yong, Xiaolan},
  title = {Bioequivalence of Two Firsekibart Subcutaneous Formulations: A Randomized, Double‐Blind, Single‐Dose, Parallel‐Group Study in Healthy Chinese Participants},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.1002/cpdd.70077}
}
Kostenlos starten →